Filing Flows › Biocryst Pharmaceuticals (BCRX) › Q3 2026 › vs Q2 2026
Biocryst Pharmaceuticals (BCRX) Q3 2026 vs Q2 2026 (quarter over quarter)
Biocryst Pharmaceuticals's revenue fell $38.0M (-17%) from $218M in Q2 2026 to $180M in Q3 2026. Operating margin 29.6% against 45.1% (-15.5 pts).
Biocryst Pharmaceuticals, Q3 2026: revenue $180M (+13% year over year), operating margin 29.6%, net earnings $37.9M, operating cash flow $33.0M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Operating margin | 29.6% | 45.1% | -15.5 pts |
| Net margin | 21.0% | 35.9% | -14.9 pts |
| Free cash flow margin | 18.2% | 47.7% | -29.5 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $180M | $218M | −$38.0M | -17% |
| Operating profit | $53.3M | $98.5M | −$45.1M | -46% |
| Costs & expenses | $127M | $120M | $7.2M | +6% |
| Pre-tax earnings | $38.6M | $79.5M | −$40.9M | -51% |
| Other expense, net | $14.7M | $19.0M | −$4.2M | -22% |
| Cost of revenue | $1.6M | $3.8M | −$2.3M | -59% |
| Research & development | $58.2M | $52.0M | $6.2M | +12% |
| SG&A | $67.2M | $64.0M | $3.2M | +5% |
| Net earnings | $37.9M | $78.4M | −$40.5M | -52% |
| Income tax | $669K | $1.1M | −$410K | -38% |
| Depreciation & amortization | $244K | $513K | −$269K | -52% |
| Share-based compensation | $14.2M | $14.7M | −$448K | -3% |
| Working capital & other | $19.4M | −$10.7M | $30.2M | — |
| Operating cash flow | $33.0M | $104M | −$71.4M | -68% |
| Free cash flow (OCF − capex) | $32.8M | $104M | −$71.4M | -69% |
| Capital expenditures | $233K | $209K | $24K | +11% |
Questions
How much did Biocryst Pharmaceuticals's revenue grow quarter over quarter in Q3 2026?
Biocryst Pharmaceuticals's revenue fell $38.0M (-17%) from $218M in Q2 2026 to $180M in Q3 2026. Operating margin 29.6% against 45.1% (-15.5 pts).